ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Amicus Therapeutics, Inc. 

1 Cedar Brook Drive

Cranbury  New Jersey  08512  U.S.A.
Phone: 609-662-2000 Fax: 609-662-2001


SEARCH JOBS

Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing novel, first-in-class, small molecules called pharmacological chaperones, to treat human genetic diseases, including lysosomal storage diseases. The Company’s lead pharmacological chaperone migalastat HCl is in Phase 3 as a monotherapy for Fabry disease. Amicus and its partner GlaxoSmithKline Plc (GSK) are conducting Phase 3 registration studies of migalastat HCl for the treatment of Fabry disease. A Phase 3 study intended to support approval of migalastat HCl in the United States is fully enrolled and results are anticipated in the third quarter of 2012. Additionally, Amicus and GSK are currently conducting a separate Phase 3 study intended to further support global registration of migalastat HCl.

Amicus continues to advance its program evaluating the use of pharmacological chaperones in combination with enzyme replacement therapy (ERT) as an expansion of the chaperone technology platform. Two chaperone-ERT combinations, migalastat HCl co-administered with ERT for Fabry disease and AT2220 (duvoglustat HCl) co-administered with ERT for Pompe disease, are currently in Phase 2 development. The Company is also investigating chaperone-ERT combinations for Gaucher disease in preclinical studies.

Amicus also has a preclinical pipeline of pharmacological chaperones for diseases of neurodegeneration, including AT3375 for Parkinson’s disease. The Company has broad, issued intellectual property around the methods, use, and composition of pharmacological chaperones to treat genetic diseases and diseases of neurodegeneration. In addition to the currently issued patents, Amicus has several patent applications pending.


 Key Statistics


Email: info@amicusrx.com
Ownership: Public

Web Site: Amicus Therapeutics, Inc.
Employees: 100
Symbol: FOLD
 









 Company News
Amicus Therapeutics, Inc. (FOLD) Provides Positive Global Regulatory Updates From European Medicines Agency And FDA Meetings For Fabry Monotherapy 3/19/2015 7:54:45 AM
Amicus Therapeutics, Inc. (FOLD) Announces Full-Year 2014 Financial Results And Corporate Updates 3/4/2015 7:30:55 AM
Amicus Therapeutics, Inc. (FOLD) To Present At Cowen and Company 35th Annual Health Care Conference 2/26/2015 8:36:27 AM
Amicus Therapeutics, Inc. (FOLD) To Announce Full-Year 2014 Financial Results On March 3, 2015 2/25/2015 8:39:15 AM
Amicus Therapeutics, Inc. (FOLD) Presents Preclinical Data On Next-Generation Pompe ERT At Worldsymposium 2015 2/10/2015 7:47:44 AM
Amicus Therapeutics, Inc. (FOLD) Announces Additional Positive Phase 3 Fabry Data On Patient Reported Outcomes At Worldsymposium 2015 2/10/2015 7:36:21 AM
Amicus Therapeutics, Inc. (FOLD) To Present At Leerink Global Healthcare Conference 2/5/2015 10:35:24 AM
Amicus Therapeutics, Inc. (FOLD) Announces Presentations And Posters At Lysosomal Disease Network WORLD Symposium 1/26/2015 7:42:33 AM
Amicus Therapeutics, Inc. (FOLD) Provides Full-Year 2015 Strategic Outlook And Financial Guidance 1/12/2015 7:39:31 AM
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac Endpoints From Fabry Monotherapy Study 011 And Long Term Extension Study 1/8/2015 7:48:51 AM
12345678910...